Mohamad Karaky
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Mohamad Karaky has a total of 53 co-authors. Here are the top co-authors by number of shared publications:
- Luda Diatchenko
Alan Edwards Centre for Research on Pain, McGill University, Montreal, QC, Canada; Department of Anesthesia, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada; Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC, Canada
4 shared publications - Francesca Montagna
Alan Edwards Centre for Research on Pain, McGill University, Montreal, QC, Canada; Department of Anesthesia, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada; Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC, Canada
2 shared publications - Jeffrey S. Mogil
Department of Psychology, McGill University, Montreal, QC, Canada.
2 shared publications Lucas V. Lima
2 shared publications- Marc Parisien
Alan Edwards Centre for Research on Pain, McGill University, Montreal, QC, Canada; Department of Anesthesia, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada; Faculty of Dental Medicine and Oral Health Sciences, McGill University, Montreal, QC, Canada
2 shared publications - Massimo Allegri
Centre Lémanique de Neuromodulation et Thérapie de la Douleur, Ensemble Hospitalier de la Côte (EHC), 1110 Morges, Switzerland
2 shared publications
Latest Publications
- Open Access
- 24 October 2026
- Published by Elsevier in British Journal of Anaesthesia
State-dependent roles of inflammation across pain conditions: insights from human transcriptomics
- 24 October 2026
- Published by Elsevier in British Journal of Anaesthesia
Open AccessState-dependent roles of inflammation across pain conditions: insights from human transcriptomics
- 6 August 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 137 (4) , 1292-1294
Prostaglandins prevent long-lasting pain in a mouse model of chronic postsurgical pain: reconciling animal and clinical evidence. Response to Br J Anaesth 2026; 137: 344–6
- 6 August 2026
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 137 (4) , 1292-1294
Prostaglandins prevent long-lasting pain in a mouse model of chronic postsurgical pain: reconciling animal and clinical evidence. Response to Br J Anaesth 2026; 137: 344–6
- 9 December 2025
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (2) , 641-652
Prostaglandins prevent long-lasting pain in a mouse model of chronic postsurgical pain
- 9 December 2025
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 136 (2) , 641-652
Prostaglandins prevent long-lasting pain in a mouse model of chronic postsurgical pain
- Open Access
- 12 June 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 133 (2) , 360-370
Genome-wide association studies with experimental validation identify a protective role for B lymphocytes against chronic post-surgical pain
- 12 June 2024
- Published by Elsevier in British Journal of Anaesthesia
- Vol. 133 (2) , 360-370
Open AccessGenome-wide association studies with experimental validation identify a protective role for B lymphocytes against chronic post-surgical pain
- Open Access
- 26 September 2022
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 18 (9) , e1010189
Prostaglandins and calprotectin are genetically and functionally linked to the Inflammatory Bowel Diseases
Background: Genome wide association studies (GWAS) have identified and validated more than 200 genomic loci associated with the inflammatory bowel disease (IBD), although for most the causal gene remains unknown. Given the importance of myeloid cells in IBD pathogenesis, the current study aimed to uncover the role of genes within IBD genetic loci that are endogenously expressed in this cell lineage. Methods: The open reading frames (ORF) of 42 genes from IBD-associated loci were expressed via lentiviral transfer in the THP-1 model of human monocytes and the impact of each of these on the cell’s transcriptome was analyzed using a RNA sequencing-based approach. We used a combination of genetic and pharmacologic approaches to validate our findings in the THP-1 line with further validation in human induced pluripotent stem cell (hiPSC)-derived-monocytes. Results: This functional genomics screen provided evidence that genes in four IBD GWAS loci (PTGIR, ZBTB40, SLC39A11 and NFKB1) are involved in controlling S100A8 and S100A9 gene expression, which encode the two subunits of calprotectin (CP). We demonstrated that increasing PTGIR expression and/or stimulating PTGIR signaling resulted in increased CP expression in THP-1. This was further validated in hiPSC-derived monocytes. Conversely, knocking-down PTGIR endogenous expression and/or inhibiting PTGIR signaling led to decreased CP expression. These analyses were extended to the known IBD gene PTGER4, whereby its specific agonist also led to increased CP expression. Furthermore, we demonstrated that the PTGIR and PTGER4 mediated control of CP expression was dependent on signaling via adenylate cyclase and STAT3. Finally, we demonstrated that LPS-mediated increases in CP expression could be potentiated by agonists of PTGIR and PTGER4, and diminished by their antagonists. Conclusion: Our results support a causal role for the PTGIR, PTGER4, ZBTB40, SLC39A11 and NFKB1 genes in IBD, with all five genes regulating the expression of CP in myeloid cells, as well as potential roles for the prostacyclin/prostaglandin biogenesis and signaling pathways in IBD susceptibility and pathogenesis.
- 26 September 2022
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 18 (9) , e1010189
Open AccessProstaglandins and calprotectin are genetically and functionally linked to the Inflammatory Bowel Diseases
Background: Genome wide association studies (GWAS) have identified and validated more than 200 genomic loci associated with the inflammatory bowel disease (IBD), although for most the causal gene remains unknown. Given the importance of myeloid cells in IBD pathogenesis, the current study aimed to uncover the role of genes within IBD genetic loci that are endogenously expressed in this cell lineage. Methods: The open reading frames (ORF) of 42 genes from IBD-associated loci were expressed via lentiviral transfer in the THP-1 model of human monocytes and the impact of each of these on the cell’s transcriptome was analyzed using a RNA sequencing-based approach. We used a combination of genetic and pharmacologic approaches to validate our findings in the THP-1 line with further validation in human induced pluripotent stem cell (hiPSC)-derived-monocytes. Results: This functional genomics screen provided evidence that genes in four IBD GWAS loci (PTGIR, ZBTB40, SLC39A11 and NFKB1) are involved in controlling S100A8 and S100A9 gene expression, which encode the two subunits of calprotectin (CP). We demonstrated that increasing PTGIR expression and/or stimulating PTGIR signaling resulted in increased CP expression in THP-1. This was further validated in hiPSC-derived monocytes. Conversely, knocking-down PTGIR endogenous expression and/or inhibiting PTGIR signaling led to decreased CP expression. These analyses were extended to the known IBD gene PTGER4, whereby its specific agonist also led to increased CP expression. Furthermore, we demonstrated that the PTGIR and PTGER4 mediated control of CP expression was dependent on signaling via adenylate cyclase and STAT3. Finally, we demonstrated that LPS-mediated increases in CP expression could be potentiated by agonists of PTGIR and PTGER4, and diminished by their antagonists. Conclusion: Our results support a causal role for the PTGIR, PTGER4, ZBTB40, SLC39A11 and NFKB1 genes in IBD, with all five genes regulating the expression of CP in myeloid cells, as well as potential roles for the prostacyclin/prostaglandin biogenesis and signaling pathways in IBD susceptibility and pathogenesis.